Guggenheim started coverage on shares of Neurocrine Biosciences (NASDAQ:NBIX) in a report released on Tuesday, June 4th, Stock Target Advisor reports. The brokerage issued a neutral rating and a $88.00 price target on the stock.
A number of other equities analysts have also recently weighed in on NBIX. Cantor Fitzgerald reaffirmed an overweight rating on shares of Neurocrine Biosciences in a research note on Wednesday, February 6th. Bank of America lowered their price target on shares of Neurocrine Biosciences from $124.00 to $117.00 and set a buy rating on the stock in a research note on Wednesday, February 6th. ValuEngine raised shares of Neurocrine Biosciences from a hold rating to a buy rating in a research note on Friday, February 8th. BidaskClub lowered shares of Neurocrine Biosciences from a hold rating to a sell rating in a research report on Saturday, February 9th. Finally, Zacks Investment Research lowered shares of Neurocrine Biosciences from a buy rating to a hold rating in a research report on Saturday, February 9th. Six equities research analysts have rated the stock with a hold rating and sixteen have issued a buy rating to the stock. The company presently has an average rating of Buy and a consensus price target of $102.16.
Shares of NBIX opened at $79.91 on Tuesday. The company has a quick ratio of 8.61, a current ratio of 8.79 and a debt-to-equity ratio of 0.96. The firm has a market cap of $7.38 billion, a PE ratio of 363.23 and a beta of 1.46. The firm has a fifty day moving average price of $81.56. Neurocrine Biosciences has a 1 year low of $64.72 and a 1 year high of $126.98.
Neurocrine Biosciences (NASDAQ:NBIX) last announced its quarterly earnings data on Monday, April 29th. The company reported ($1.12) earnings per share (EPS) for the quarter, missing the consensus estimate of ($1.05) by ($0.07). The firm had revenue of $138.40 million during the quarter, compared to analyst estimates of $136.77 million. Neurocrine Biosciences had a negative net margin of 7.56% and a negative return on equity of 9.14%. The business’s quarterly revenue was up 94.7% compared to the same quarter last year. During the same period in the prior year, the firm posted ($0.47) earnings per share. On average, sell-side analysts anticipate that Neurocrine Biosciences will post -0.08 EPS for the current fiscal year.
In other news, insider Haig P. Bozigian sold 2,100 shares of the stock in a transaction dated Tuesday, June 18th. The shares were sold at an average price of $87.82, for a total transaction of $184,422.00. Following the transaction, the insider now directly owns 144,076 shares in the company, valued at approximately $12,652,754.32. The sale was disclosed in a legal filing with the SEC, which is available at this hyperlink. Also, insider Haig P. Bozigian sold 17,268 shares of the stock in a transaction dated Thursday, June 13th. The stock was sold at an average price of $82.62, for a total transaction of $1,426,682.16. Following the transaction, the insider now owns 157,812 shares in the company, valued at $13,038,427.44. The disclosure for this sale can be found here. Over the last 90 days, insiders sold 162,100 shares of company stock worth $12,999,576. 4.30% of the stock is owned by insiders.
Institutional investors and hedge funds have recently bought and sold shares of the stock. Eaton Vance Management increased its position in Neurocrine Biosciences by 20.8% during the 4th quarter. Eaton Vance Management now owns 129,434 shares of the company’s stock worth $9,243,000 after purchasing an additional 22,280 shares in the last quarter. NumerixS Investment Technologies Inc increased its position in Neurocrine Biosciences by 75.2% during the 4th quarter. NumerixS Investment Technologies Inc now owns 3,300 shares of the company’s stock worth $226,000 after purchasing an additional 1,416 shares in the last quarter. Brinker Capital Inc. acquired a new stake in Neurocrine Biosciences during the 4th quarter worth approximately $705,000. Voloridge Investment Management LLC acquired a new stake in Neurocrine Biosciences during the 4th quarter worth approximately $4,331,000. Finally, Emory University increased its position in Neurocrine Biosciences by 11.9% during the 1st quarter. Emory University now owns 28,287 shares of the company’s stock worth $2,492,000 after purchasing an additional 2,998 shares in the last quarter. 95.86% of the stock is owned by hedge funds and other institutional investors.
About Neurocrine Biosciences
Neurocrine Biosciences, Inc discovers and develops pharmaceuticals for the treatment of neurological and endocrine-related diseases and disorders in the United States. The company offers INGREZZA (valbenazine), a vesicular monoamine transporter 2 inhibitor (VMAT2), which is used for the treatment of movement disorders; ORILISSA, a gonadotropin-releasing hormone (GnRH) antagonist for use in women's health.
Read More: Trade War
Receive News & Ratings for Neurocrine Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Neurocrine Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.